Literature DB >> 11835447

Effects of immobility on sensory and motor symptoms of restless legs syndrome.

Martin Michaud1, Gilles Lavigne, Alex Desautels, Gaétan Poirier, Jacques Montplaisir.   

Abstract

Restless legs syndrome (RLS) is defined by an irresistible need to move associated with leg paresthesia. Two additional features are essential for diagnosis: (1) worsening of symptoms at rest with temporary relief by activity, and (2) worsening of symptoms during the evening and/or during the night. The suggested immobilization test (SIT) has been developed to evaluate the presence of these criteria. This test quantifies leg movements and leg discomfort during a 1-hour period of immobility prior to bedtime. We used the SIT to evaluate the effects of immobility on leg discomfort and leg movements experienced by 19 patients with RLS and 19 control subjects. Results show that immobility significantly worsens both leg discomfort and periodic leg movements (PLM) in patients with RLS but not in controls. Patients with RLS showed a higher leg discomfort score (32.6 +/- 15.1 mm vs. 5.7 +/- 7.9 mm; P < 0.00001), a greater maximum leg discomfort value (63.4 +/- 27.4 mm vs. 13.7 +/- 23.0 mm; P < 0.00001) and a greater PLM index (88.4 +/- 62.6 vs. 10.4 +/- 20.6; P < 0.00004) than control subjects. These results further validate the use of the SIT as a diagnostic and research tool for RLS and confirm the contention of the International RLS study group that RLS symptoms worsen at rest. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Year:  2002        PMID: 11835447     DOI: 10.1002/mds.10004

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

Review 1.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

2.  Neurological disorders: towards a mechanistic understanding of restless legs syndrome.

Authors:  Paul J Shaw; Stephen P Duntley
Journal:  Curr Biol       Date:  2012-06-19       Impact factor: 10.834

3.  Effect of sensory stimuli on restless legs syndrome: a randomized crossover study.

Authors:  Anouk D Rozeman; Truus Ottolini; Diana C Grootendorst; Oscar J M Vogels; Roselyne M Rijsman
Journal:  J Clin Sleep Med       Date:  2014-08-15       Impact factor: 4.062

4.  Apomorphine in idiopathic restless legs syndrome: an exploratory study.

Authors:  G G Tribl; T Sycha; N Kotzailias; J Zeitlhofer; E Auff
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

5.  Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice.

Authors:  Mark P DeAndrade; Russell L Johnson; Erica L Unger; Li Zhang; Thomas van Groen; Karen L Gamble; Yuqing Li
Journal:  Hum Mol Genet       Date:  2012-06-07       Impact factor: 6.150

Review 6.  Psychiatric aspects of Parkinson's disease--an update.

Authors:  Anette Schrag
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 7.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Validation of the Multiple Suggested Immobilization Test: A Test for the Assessment of Severity of Restless Legs Syndrome (Willis-Ekbom Disease).

Authors:  Diego Garcia-Borreguero; Ralf Kohnen; Lindsay Boothby; Desislava Tzonova; Oscar Larrosa; Elmar Dunkl
Journal:  Sleep       Date:  2013-07-01       Impact factor: 5.849

10.  Transdermal rotigotine for the perioperative management of restless legs syndrome.

Authors:  Birgit Högl; Wolfgang H Oertel; Erwin Schollmayer; Lars Bauer
Journal:  BMC Neurol       Date:  2012-09-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.